Skip to main content
Frontiers in Immunology logoLink to Frontiers in Immunology
. 2024 Feb 28;15:1389603. doi: 10.3389/fimmu.2024.1389603

Corrigendum: Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing

Michel Demeule 1, Jean-Christophe Currie 1, Cyndia Charfi 1, Alain Zgheib 2, Isabelle Cousineau 2, Véronique Lullier 2, Richard Béliveau 2, Christian Marsolais 1, Borhane Annabi 2,*
PMCID: PMC10935994  PMID: 38482002

In the published article, there was an error in Figures 1A, C as published. In the original Figure 1A : The colored text related to the color-coded dots underneath the x-axis was not aligned. In the original Figure 1C : The small blue box legends needed to be removed from the inserts of the first line of pictures. The corrected Figures 1A, C and its caption “ Figure 1 Sustained and prolonged antitumor activity of TH1902 in an immunosuppressed MDA-MB-231 TNBC-derived xenograft model.” appear below.

Figure 1.

Figure 1

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Immunology are provided here courtesy of Frontiers Media SA

RESOURCES